L&G Healthcare Breakthrough UCITS ETF (ETR:XMLH)
Germany · Delayed Price · Currency is EUR 10.73
+0.05 (0.45%)
Aug 21, 2025, 5:36 PM CET
0.45% (1Y)
| Assets | 78.76M |
| Expense Ratio | 0.49% |
| PE Ratio | 25.76 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -1.27% |
| Volume | 564 |
| Open | 10.76 |
| Previous Close | 10.68 |
| Day's Range | 10.72 - 10.76 |
| 52-Week Low | 8.88 |
| 52-Week High | 12.60 |
| Beta | 0.37 |
| Holdings | 66 |
| Inception Date | Jun 17, 2019 |
About XMLH
The L&G Healthcare Breakthrough UCITS ETF (the ETF) aims to track the performance of the ROBO Global Healthcare Technology and Innovation Index TR (the Index).
Asset Class Equity
Category Health Care
Stock Exchange Deutsche Börse Xetra
Ticker Symbol XMLH
Provider L&G
Index Tracked ROBO Global Healthcare Technology and Innovation ETF
Performance
XMLH had a total return of -1.27% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.55%.
Top 10 Holdings
23.30% of assets| Name | Symbol | Weight |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.70% |
| STAAR Surgical Company | STAA | 2.56% |
| Axogen, Inc. | AXGN | 2.52% |
| Medpace Holdings, Inc. | MEDP | 2.30% |
| JD Health International Inc. | 6618 | 2.26% |
| CRISPR Therapeutics AG | CRSP | 2.25% |
| Artivion, Inc. | AORT | 2.21% |
| Guardant Health, Inc. | GH | 2.20% |
| Tempus AI, Inc. | TEM | 2.16% |
| Thermo Fisher Scientific Inc. | TMO | 2.16% |